Lambert-Eaton Myasthenic Syndrome:Clinical Diagnosis,Immune-Mediated Mechanisms,and Update on Therapies
Ann Neurol 37:S63-S73, Sanders,D.B., 1995
Paraneoplastic Neurological Syndromes
Clin Exp Immunol 175:336-348, Leypoldt, F. & Wandinger, K.-P., 2014
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990
Plasma Exchange & Immunosuppressive Drug Treatment in the Lambert-Eaton Myasthenic Syndrome
Neurol 34:480-485, Newsom-Davis,J.,et al, 1984
Plasmapheresis & Immunosuppressive Drug Therapy in the Eaton-Lambert Syndrome
Ann Neurol 11:570-575, Da,P.C.,et al, 1982
Eaton-Lambert Myasthenic Syndrome:Long-term Treatment of Three Patients with Prednisone
Ann Neurol 10:448-453, Streib,E.W.,et al, 1981
Important Advances in Clinical Medicine
West J Med 123:128, Mosier,J.M.,et al, 1975